Sparsentan is expected to be funded in England by 27 June 2025, within 90 days of the final guidance publication. IgA ...

The National Institute for Health and Care Excellence (NICE) has recommended FILSPARI (sparsentan) for use in the NHS in ...

NICE reversed its earlier decision on sparsentan for treating primary immunoglobulin A nephropathy after additional evidence ...

Proteinuria is a major risk factor for IgA nephropathy progression ... CSL Vifor expects to launch sparsentan in the UK in the second half of 2025; commercial stock will be available from July ...

One advantage of sparsentan over other medications for IgA nephropathy is that it does not suppress your immune system, lowering your risk for infections. Iptacopan acts on a specific process in ...

Sparsentan is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline for adults with primary IgA nephropathy who are at risk for disease progression.

This second of four exclusive episodes explores whether sparsentan can leapfrog renin-angiotensin system (RAS) blockade and how emerging biomarkers may reshape management of IgA nephropathy.

About IgA Nephropathy (IgAN ... controlled clinical trial evaluating the safety and efficacy of 400 mg of sparsentan, compared to 300 mg of irbesartan (an angiotensin II receptor blocker(ARB ...

CSL Vifor is pleased to announce that the National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending that sparsentan can be used in the NHS in England as ...